

RESEARCH STUDIES

1. What is the name of the study?
Citalopram for Agitation in Alzheimer's Disease
2. When does the recruitment start and finish?
October, 2009 – Approximately 3 years.
3. How is the study being funded?
National Institute of Aging (NIA)
National Institute of Mental Health (NIMH)
4. What is being investigated?
To determine if a medication called Citalopram is helpful to people with Alzheimer's disease who are experiencing symptoms of significant agitation. Citalopram is a Health Canada approved antidepressant medication for the treatment of mood disorders, however, it is not yet an approved treatment for significant agitation in Alzheimer's Disease.
5. Why is the study important?
 - To assist families living with Alzheimer's disease.
 - To learn if a medication called Citalopram helps people with Alzheimer's disease and their agitation.
6. Who can participate?
People who suffer from Alzheimer's disease and symptoms of agitation or irritability. Participants must be accompanied by a caregiver.
7. Who cannot participate?
 - People who have had a Major Depressive Episode
 - Psychosis (delusions or hallucinations) requiring antipsychotic treatment.
 - Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll.
8. What is required of the participants?
The participant and their caregiver will be asked to come to the clinic for a 1 hour screening visit. If they are eligible and agree to be in the study, they will be prescribed the study medication and receive helpful support and education from experts in Alzheimer's disease. Participants are required to come back to the clinic for more visits at 3, 6 and 9 weeks. The participant and the caregiver will be contacted by telephone between visits.
9. What are the potential benefits and limitations of participating?
Qualified participants will:
 - Participate at no cost to them.
 - Receive expert consultations from a specialist in Alzheimer's, education and support.
 - Receive free memory testing and diagnosis.
 - Be compensated for their time and transportation will be provided
10. Has the study been approved by an ethics committee? (please provide details)
The study has been approved by the CAMH research ethics board as well as Health Canada.
11. How large is the study?
The project is being conducted at the University of Toronto and 7 other academic centers in the United States. It involves participation of more than 200 patients.

12. Where are the study sites?

University of Toronto
Johns Hopkins University
Stanford University
Columbia University
University of Southern California
University of Pennsylvania
Medical University of South Carolina
University of Rochester

13. Where can one obtain more information?

If you are interested in learning more about this study or how to enroll,

Please contact Dielle Miranda at **416-535-8501 ext 3120**

Or e-mail **Dielle_Miranda@CAMH.net**

*The contents of this document are provided for information purposes only
by the Alzheimer Society of Toronto and do not represent an endorsement or a recommendation with
respect to the research study and/or the claims and properties thereof.*

Alzheimer Society of Toronto
20 Eglinton Ave West, 16th floor, Toronto Ontario M4R 1K8
416-322-6560
write@alzheimerontario.org